Generic Drug Giant
-
{
- All
- News
- Videos
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Johnson & Johnson Loses Key Tuberculosis Drug Patent In India
The Indian Patent Office on Thursday rejected US pharmaceutical giant Johnson and Johnson's application to extend its patent on a key tuberculosis treatment, allowing local companies to make cheaper generic versions.
-
Maggi Ban Not In Retaliation To European Union's Clampdown: Government
Government today rejected suggestions that the five-month ban Swiss giant Nestle's Maggi noodles was in retaliation to the European Union's clampdown on marketing of 700 generic drugs for alleged manipulation of clinical trials by GVK Bio.
-
India defends rejection of Novartis patent bid
An Indian court was fully justified to reject a patent bid by Swiss drug giant Novartis last week, India's trade and industry minister insisted in Geneva on Monday, defending the country's generic drug business.
-
Supreme Court backs generics in Novartis drug patent ruling
India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic drugs and save lives in developing nations.
-
Supreme Court's verdict on Novartis' plea for patent of cancer drug expected today
The Supreme Court will pronounce today its verdict on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India and restraining Indian companies from manufacturing generic drugs.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Johnson & Johnson Loses Key Tuberculosis Drug Patent In India
The Indian Patent Office on Thursday rejected US pharmaceutical giant Johnson and Johnson's application to extend its patent on a key tuberculosis treatment, allowing local companies to make cheaper generic versions.
-
Maggi Ban Not In Retaliation To European Union's Clampdown: Government
Government today rejected suggestions that the five-month ban Swiss giant Nestle's Maggi noodles was in retaliation to the European Union's clampdown on marketing of 700 generic drugs for alleged manipulation of clinical trials by GVK Bio.
-
India defends rejection of Novartis patent bid
An Indian court was fully justified to reject a patent bid by Swiss drug giant Novartis last week, India's trade and industry minister insisted in Geneva on Monday, defending the country's generic drug business.
-
Supreme Court backs generics in Novartis drug patent ruling
India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic drugs and save lives in developing nations.
-
Supreme Court's verdict on Novartis' plea for patent of cancer drug expected today
The Supreme Court will pronounce today its verdict on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India and restraining Indian companies from manufacturing generic drugs.
